Passage Bio is no longer a gene-therapy operating company in any meaningful sense. After a Type C meeting in which the Food and Drug Administration refused a single-arm registrational path for PBFT02 in frontotemporal dementia with granulin mutations, management wound the remaining programs, cut most of the staff, and signed an all-stock reverse merger with private Remix Therapeutics. The listed equity is now a thin stub on someone else's RNA-processing pipeline plus a contingent value right on leftover pediatric licenses. That is a recapitalization, not a clinical continuation.
Legacy holders keep only a mid-single-digit slice of the combined company. Remix equity plus the concurrent private placement take the rest, and the September amendment left those economics intact while adding a two-step tax structure and pre-funded warrants. Cash at mid-year sits near the entire market value of the common, yet the liquidity note still raises substantial doubt unless the merger or another large raise is completed. The market is not paying a going-concern premium. It is paying a deal-completion option on a very small residual claim.
The June quarter narrowed the loss because research spending collapsed and lease-exit gains offset part of the wind-down, while general costs rose on banker and counsel fees. Combined cash after the concurrent raise is framed as enough to carry Remix through REM-422 readouts into the next several years. The open question is whether a mid-single-digit stub plus a Gemma-tied contingent right is worth more than a failed-deal liquidation of a remote-only shell.